. 1. Synthesis of a series of targeted and non-targeted PEG-PCL miktoarm polymers: PEG2-PCL3.5-Br: A solution of compound 6 (50mg, 0.02mmoles) in dry toluene (2 ml) was placed in a flame-dried two neck round bottom flask fitted with a condenser. The solution was degassed by evacuation, and distilled ε-caprolactone (0.07ml, 0.67mmoles) was added under nitrogen with a syringe through the rubber septum. A nitrogen purged solution of Sn(II) 2-ethylhexanoate (catalytic) in toluene (1 ml) was then added to the reaction flask, and the mixture was refluxed for 24 h. The reaction mixture was then cooled to room temperature, and the solvent was removed under vacuum. The product was dissolved in dichloromethane and precipitated in cold methanol. The polymer was filtered and washed with diethylether to yield a white powder. GPC: Mn = 5992, Polydispersity Index (PDI) =1.2.
PEG2-PCL3.8-Br:
Compound 6 (50mg, 0.02mmoles) and ε-caprolactone (0.08ml, 0.74mmoles) were reacted together using the above mentioned procedure for ring opening polymerization. GPC: Mn = 6252, PDI =1.3.
PEG2-PCL4.4-Br:
Compound 6 (50mg, 0.02mmoles) and ε-caprolactone (0.10ml, 0.88mmoles) were reacted together using the above mentioned procedure for ring opening polymerization. GPC: Mn = 6911, PDI =1.3.
PEG2-PCL5.5-Br:
Compound 6 (50mg, 0.02mmoles) and ε-caprolactone (0.12ml, 1.10mmoles) were reacted together using the above mentioned procedure for ring opening polymerization. GPC: Mn = 7932, PDI =1.4.
PEG2-PCL7.0-Br:
Compound 6 (50mg, 0.02mmoles) and ε-caprolactone (0.15ml, 1.37mmoles) were reacted together using the above mentioned procedure for ring opening polymerization. GPC: Mn = 9574, PDI =1.3.
PEG2-PCL7.8-Br: Compound 6 (50mg, 0.02mmoles) and ε-caprolactone (0.18ml, 1.58mmoles) were reacted together using the above mentioned procedure for ring opening polymerization. GPC: Mn = 10247, PDI =1.2.
PEG2-PCL3.5-TPP + Br -:
A solution of PEG2K_PCL3500_Br (100mg, 0.02mmoles) and triphenyl phosphine (TPP) (8.8mg, 0.03mmoles) in acetonitrile (ACN) was refluxed for 48 h. The solvent was then evaporated and the residue was washed several times with hexanes and diethylether to remove excess of TPP. The white solid was then dried under vacuum. GPC: Mn = 6022, PDI =1.3.
PEG2-PCL3.8-TPP + Br -: PEG2K_PCL3800_Br (100mg, 0.02mmoles) and TPP (8.4mg, 0.03mmoles) were reacted together using a similar procedure as mentioned above to afford the product as white solid. GPC: Mn = 6284, PDI =1.4.
PEG2-PCL4.4-TPP + Br -:
PEG2K_PCL4400_Br (100mg, 0.01mmoles) and TPP (7.6mg, 0.03mmoles) were reacted together using a similar procedure as mentioned above to afford the product as white solid. GPC: Mn = 7353, PDI =1.3.
PEG2-PCL5
.5-TPP + Br -: PEG2K_PCL5500_Br (100mg, 0.02mmoles) and TPP (6.6mg, 0.03mmoles) were reacted together using a similar procedure as mentioned above to afford the product as white solid. GPC: Mn = 8374, PDI =1.4.
PEG2-PCL7.0-TPP + Br -: PEG2K_PCL7000_Br (100mg, 0.01mmoles) and TPP (5.5mg, 0.02mmoles) were reacted together using a similar procedure as mentioned above to afford the product as white solid. GPC: Mn = 11140, PDI =1.6.
PEG2-PCL7.8-TPP + Br -:
PEG2K_PCL7800_Br (100mg, 0.01mmoles) and TPP (5.1mg, 0.02mmoles) were reacted together using a similar procedure as mentioned above to afford the product as white solid. GPC: Mn = 12072, PDI =1.6. . Mitochondrial metabolic activity (%) is expressed relative to controls (untreated cells that were set to 100%, n=9). The data are presented as mean ±SEM obtained from at least three independent experiments performed in triplicates. Statistically significant differences are indicated by p** <0.01, p*** <0.001. 
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